REG - Immupharma PLC Legal & General Grp - Holding(s) in Company <Origin Href="QuoteRef">IMM.L</Origin> <Origin Href="QuoteRef">LGEN.L</Origin>

Legal & GeneralAnnouncement

17/02/2017 14:05

RNS Number : 2167X
Immupharma PLC
17 February 2017

17 FEBRUARY 2017
NOTIFICATION OF INTEREST BY LEGAL & GENERAL
ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc ("L&G") confirming its holding in ImmuPharma of 3,774,714 million Ordinary Shares in the capital of the Company.
Full disclosure of the TR1 is shown below:


1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ImmuPharma Plc
2. Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
Yes
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):


3. Full name of person(s) subject to the
notification obligation:
Legal & General Group Plc (L&G)
4. Full name of shareholder(s)
(if different from 3.):
Legal & General Assurance Society Limited (LGAS)
5. Date of the transaction and date on
which the threshold is crossed or
reached:
15 February 2017
6. Date on which issuer notified:
16 February 2017
7. Threshold(s) that is/are crossed or
reached: 
L&G (Below 3%)


8. Notified details:
A: Voting rights attached to shares
Class/type of
shares

if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of shares
Number of voting
rights
% of voting rights
Direct
Indirect
Direct
Indirect
ORD GBP 0.10
3,774,714
Below 3% 
Below 3% 
-
Below 3%
-

B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
Expiration
date
Exercise/
Conversion Period
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
% of voting
rights






C: Financial Instruments with similar economic effect to Qualifying Financial Instruments 
Resulting situation after the triggering transaction
Type of financial
instrument
Exercise price
Expiration date 
Exercise/
Conversion period 
Number of voting rights instrument refers to
% of voting rights 




Nominal
Delta



Total (A+B+C)
Number of voting rights
Percentage of voting rights
Below 3% 


9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
Legal & General Group Plc (Direct and Indirect) (Group) ( Below 5% = Total Position) 

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( Below 5% = Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( Below 5% = Total Position)

Legal & General Group Plc (Direct) (L&G) ( Below 3% = LGAS, LGPL & PMC)
Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD) 
Legal & General Insurance Holdings Limited (Direct) (LGIH) 
Legal & General Assurance (Pensions Management) Limited (PMC) 
Legal & General Assurance Society Limited (LGAS & LGPL) 

Legal & General Pensions Limited (Direct) (LGPL)

Proxy Voting:
10. Name of the proxy holder:
N/A
11. Number of voting rights proxy holder will cease to hold:
N/A
12. Date on which proxy holder will cease to hold
voting rights:
N/A


13. Additional information:
Notification using the total voting rights figure of 124,638,362 
14. Contact name:
Victoria Davies (LGIM)
15. Contact telephone number:
029 2035 4147
-Ends-
For further information please contact:
ImmuPharma plc (www.immupharma.org)
+ 44 (0) 20 7152 4080
Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations
Twitter: @immupharma
+ 44 (0) 7721 413496
Northland Capital Partners Limited (NOMAD & Broker)
Patrick Claridge, David Hignell, Michael Mackintosh, Corporate Finance
Rob Rees, Corporate Broking
+44 (0)20 3861 6625










This information is provided by RNS
The company news service from the London Stock Exchange
  END
HOLZDLFFDLFBBBF